Ananta Medicare has recognized antimicrobial resistance (AMR) as a serious global challenge and is aligning its research efforts to address it. At its Sriganganagar site—a dedicated cephalosporin production facility with WHO, EU, PIC/S GMP certifications—Ananta is exploring how optimized β-lactam antibiotic design, novel sulbactam/tazobactam combinations, and refined dosing can curb resistance emergence. By innovating formulations like ceftriaxone-sulbactam and cefoperazone-sulbactam, it aims to enhance efficacy against resistant bacterial strains. These efforts are supported by molecular laboratory screenings to detect β-lactamase producers and assess minimum inhibitory concentrations (MICs) for different pathogens.
In addition, Ananta is integrating a “One Health” perspective—ensuring antibiotic stewardship from manufacturing through environmental management. With plans to adopt advanced wastewater treatment and reduce antibiotic residues, the company mirrors national priorities aimed at minimizing pharmaceutical pollutants that foster microbial resistance . Internally, Ananta is developing antimicrobial stewardship protocols in collaboration with hospital networks, aligning with India’s National Action Plan (NAP) to promote rational antibiotic use and restrict over-the-counter access .
While currently focused on generics, Ananta is steering toward innovation—upgrading existing antibiotics to better combat resistant infections, investing in diagnostic compatibility, and partnering with academic labs to explore resistance mechanisms. These strategic R&D initiatives position Ananta as a responsible player contributing to India’s fight against AMR.